MR Imaging–Detectable Metabolic Alterations in Attention Deficit/Hyperactivity Disorder: From Preclinical to Clinical Studies

References

1. 1.↵
   1. Oades RD

   . Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity disorder: a psychophysiological and neuropsychological viewpoint on development. Behav Brain Res 1998;94:83–95

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Castellanos FX,
   2. Sonuga-Barke EJ,
   3. Milham MP,
   4. et al

   . Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 2006;10:117–23

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Sonuga-Barke EJ

   . Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005;57:1231–38

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Casey BJ,
   2. Durston S

   . From behavior to cognition to the brain and back: what have we learned from functional imaging studies of attention deficit hyperactivity disorder? Am J Psychiatry 2006;163:957–60

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Sagvolden T,
   2. Aase H,
   3. Zeiner P,
   4. et al

   . Altered reinforcement mechanisms in attention-deficit/hyperactivity disorder. Behav Brain Res 1998;94:61–71

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Accardo P,
   2. Blondis TA

   . What's all the fuss about Ritalin? J Pediatr 2001;138:6–9

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Scheffler RM,
   2. Hinshaw SP,
   3. Modrek S,
   4. et al

   . The global market for ADHD medications. Health Aff (Millwood) 2007;26:450–57

   Abstract/FREE Full Text
8. 8.↵
   1. Altabella L,
   2. Strolin S,
   3. Villani N,
   4. et al

   . Magnetic resonance imaging and spectroscopy in the study in ADHD syndrome: a short review. Biophysics and Bioeng Letters 2011;4:23–34
9. 9.↵
   1. Bush G

   . Cingulate, frontal, and parietal cortical dysfunction in attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69:1160–67

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Hart H,
    2. Radua J,
    3. Mataix-Cols D,
    4. et al

    . Meta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD). Neurosci Biobehav Rev 2012;36:2248–56

    CrossRefPubMed
11. 11.↵
    1. de Graaf RA

    . In Vivo NMR Spectroscopy: Principles and Techniques. Chichester, UK: John Wiley; 2008
12. 12.↵
    1. Posse S,
    2. Otazo R,
    3. Dager SR,
    4. et al

    . MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging 2013;37:1301–25

    CrossRefPubMed
13. 13.↵
    1. Canese R,
    2. Pisanu ME,
    3. Mezzanzanica D,
    4. et al

    . Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging. NMR Biomed 2012;25:632–42

    CrossRefPubMed
14. 14.↵
    1. Scheidegger O,
    2. Wingeier K,
    3. Stefan D,
    4. et al

    . Optimized quantitative magnetic resonance spectroscopy for clinical routine. Magn Reson Med 2013;70:25–32

    CrossRefPubMed
15. 15.↵
    1. Puts NA,
    2. Edden RA

    . In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc 2012;60:29–41

    CrossRefPubMed
16. 16.↵
    1. Blüml S,
    2. Wisnowski JL,
    3. Nelson MD Jr.,
    4. et al

    . Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy. Cereb Cortex 2013;23:2944–55

    Abstract/FREE Full Text
17. 17.↵
    1. Horská A,
    2. Kaufmann WE,
    3. Brant LJ,
    4. et al

    . In vivo quantitative proton MRSI study of brain development from childhood to adolescence. J Magn Reson Imaging 2002;15:137–43

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Vyas NS,
    2. Patel NH,
    3. Herscovitch P,
    4. et al

    . Recent developments in neurochemical imaging in schizophrenia: an update. Curr Med Chem 2013;20:351–56

    PubMed
19. 19.↵
    1. Kraguljac NV,
    2. Reid M,
    3. White D,
    4. et al

    . Neurometabolites in schizophrenia and bipolar disorder: a systematic review and meta-analysis. Psychiatry Res 2012;203:111–25

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Baruth JM,
    2. Wall CA,
    3. Patterson MC,
    4. et al

    . Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review. Autism Res 2013;6:119–33

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Biederman J,
    2. Faraone SV

    . Attention-deficit hyperactivity disorder. Lancet 2005;366:237–48

    CrossRefPubMedWeb of Science
22. 22.↵
    1. van der Staay FJ

    . Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res Rev 2006;52:131–59

    CrossRefPubMed
23. 23.↵
    1. Shaywitz BA,
    2. Yager RD,
    3. Klopper JH

    . Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science 1976;191:305–08

    Abstract/FREE Full Text
24. 24.↵
    1. Fan X,
    2. Bruno KJ,
    3. Hess EJ

    . Rodent models of ADHD. Curr Top Behav Neurosci 2012;9:273–300

    PubMed
25. 25.↵
    1. Adriani W,
    2. Boyer F,
    3. Gioiosa L,
    4. et al

    . Increased impulsive behavior and risk proneness following lentivirus-mediated dopamine transporter over-expression in rats' nucleus accumbens. Neuroscience 2009;159:47–58

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Adriani W,
    2. Boyer F,
    3. Leo D,
    4. et al

    . Social withdrawal and gambling-like profile after lentiviral manipulation of DAT expression in the rat accumbens. Int J Neuropsychopharmacol 2010;13:1329–42

    Abstract/FREE Full Text
27. 27.↵
    1. Adriani W,
    2. Zoratto F,
    3. Laviola G

    . Brain processes in discounting: consequences of adolescent methylphenidate exposure. Curr Top Behav Neurosci 2012;9:113–43

    PubMed
28. 28.↵
    1. Adriani W,
    2. Canese R,
    3. Podo F,
    4. et al

    . 1H MRS-detectable metabolic brain changes and reduced impulsive behavior in adult rats exposed to methylphenidate during adolescence. Neurotoxicol Teratol 2007;29:116–25

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Adriani W,
    2. Leo D,
    3. Greco D,
    4. et al

    . Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 2006;31:1946–56

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Perlov E,
    2. Philipsen A,
    3. Matthies S,
    4. et al

    . Spectroscopic findings in attention-deficit/hyperactivity disorder: review and meta-analysis. World J Biol Psychiatry 2009;10:355–65

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Hammerness P,
    2. Biederman J,
    3. Petty C,
    4. et al

    . Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study. CNS Neurosci Ther 2012;18:34–40

    CrossRefPubMed
32. 32.↵
    1. Arcos-Burgos M,
    2. Londono AC,
    3. Pineda DA,
    4. et al

    . Analysis of brain metabolism by proton magnetic resonance spectroscopy (1H-MRS) in attention-deficit/hyperactivity disorder suggests a generalized differential ontogenic pattern from controls. Atten Defic Hyperact Disord 2012;4:205–12

    CrossRefPubMed
33. 33.↵
    1. Krain AL,
    2. Castellanos FX

    . Brain development and ADHD. Clin Psychol Rev 2006;26:433–44

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Tafazoli S,
    2. O'Neill J,
    3. Bejjani A,
    4. et al

    . 1H MRSI of middle frontal gyrus in pediatric ADHD. J Psychiatr Res 2013;47:505–12

    CrossRefPubMed
35. 35.↵
    1. Soliva JC,
    2. Moreno A,
    3. Fauquet J,
    4. et al

    . Cerebellar neurometabolite abnormalities in pediatric attention/deficit hyperactivity disorder: a proton MR spectroscopic study. Neurosci Lett 2010;470:60–64

    CrossRefPubMed
36. 36.↵
    1. Provencher SW

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–79

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Provencher SW

    . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260–64

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Carrey NJ,
    2. MacMaster FP,
    3. Gaudet L,
    4. et al

    . Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:11–17

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Yang P,
    2. Wu MT,
    3. Dung SS,
    4. et al

    . Short-TE proton magnetic resonance spectroscopy investigation in adolescents with attention-deficit hyperactivity disorder. Psychiatry Res 2010;181:199–203

    CrossRefPubMed
40. 40.↵
    1. Hesslinger B,
    2. Thiel T,
    3. Tebartz van Elst L,
    4. et al

    . Attention-deficit disorder in adults with or without hyperactivity: where is the difference? A study in humans using short echo (1)H-magnetic resonance spectroscopy. Neurosci Lett 2001;304:117–19

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Edden RA,
    2. Crocetti D,
    3. Zhu H,
    4. et al

    . Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2012;69:750–53

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Stanley JA,
    2. Kipp H,
    3. Greisenegger E,
    4. et al

    . Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. Arch Gen Psychiatry 2008;65:1419–28

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Stanley JA,
    2. Kipp H,
    3. Greisenegger E,
    4. et al

    . Regionally specific alterations in membrane phospholipids in children with ADHD: an in vivo 31P spectroscopy study. Psychiatry Res 2006;148:217–21

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Colla M,
    2. Ende G,
    3. Alm B,
    4. et al

    . Cognitive MR spectroscopy of anterior cingulate cortex in ADHD: elevated choline signal correlates with slowed hit reaction times. J Psychiatr Res 2008;42:587–95

    CrossRefPubMed
45. 45.↵
    1. Perlov E,
    2. Philipsen A,
    3. Hesslinger B,
    4. et al

    . Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder: a magnet resonance spectroscopy study. J Psychiatr Res 2007;41:934–41

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Dramsdahl M,
    2. Ersland L,
    3. Plessen KJ,
    4. et al

    . Adults with attention-deficit/hyperactivity disorder: a brain magnetic resonance spectroscopy study. Front Psychiatry 2011;2:65

    PubMed
47. 47.↵
    1. Kronenberg G,
    2. Ende G,
    3. Alm B,
    4. et al

    . Increased NAA and reduced choline levels in the anterior cingulum following chronic methylphenidate: a spectroscopic test-retest study in adult ADHD. Eur Arch Psychiatry Clin Neurosci 2008;258:446–50

    CrossRefPubMed
48. 48.↵
    1. Perlov E,
    2. Tebarzt van Elst L,
    3. Buechert M,
    4. et al

    . H(1)-MR-spectroscopy of cerebellum in adult attention deficit/hyperactivity disorder. J Psychiatr Res 2010;44:938–43

    CrossRefPubMed
49. 49.↵
    1. Yin HH,
    2. Knowlton BJ,
    3. Balleine BW

    . Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci 2004;19:181–89

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Cardinal RN,
    2. Winstanley CA,
    3. Robbins TW,
    4. et al

    . Limbic corticostriatal systems and delayed reinforcement. Ann N Y Acad Sci 2004;1021:33–50

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Bjork JM,
    2. Knutson B,
    3. Fong GW,
    4. et al

    . Incentive-elicited brain activation in adolescents: similarities and differences from young adults. J Neurosci 2004;24:1793–802

    Abstract/FREE Full Text
52. 52.↵
    1. Dalley JW,
    2. Cardinal RN,
    3. Robbins TW

    . Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004;28:771–84

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Arnsten AF

    . Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009;23(suppl 1):33–41

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Seamans JK,
    2. Lapish CC,
    3. Durstewitz D

    . Comparing the prefrontal cortex of rats and primates: insights from electrophysiology. Neurotox Res 2008;14:249–62

    CrossRefPubMedWeb of Science
55. 55.↵
    1. Ridderinkhof KR,
    2. van den Wildenberg WP,
    3. Segalowitz SJ,
    4. et al

    . Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn 2004;56:129–40

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Frodl T,
    2. Skokauskas N

    . Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr Scand 2012;125:114–26

    CrossRefPubMedWeb of Science
57. 57.↵
    1. Hoerst M,
    2. Weber-Fahr W,
    3. Tunc-Skarka N,
    4. et al

    . Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry 2010;67:946–54

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Carlsson ML

    . On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:5–26

    CrossRefPubMed
59. 59.↵
    1. Todd RD,
    2. Botteron KN

    . Is attention-deficit/hyperactivity disorder an energy deficiency syndrome? Biol Psychiatry 2001;50:151–58

    CrossRefPubMed
60. 60.↵
    1. Silveri MM,
    2. Sneider JT,
    3. Crowley DJ,
    4. et al

    . Frontal lobe gamma-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition. Biol Psychiatry 2013;74:296–304

    CrossRefPubMed
61. 61.↵
    1. Dautry C,
    2. Vaufrey F,
    3. Brouillet E,
    4. et al

    . Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 2000;20:789–99

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Fagundes AO,
    2. Rezin GT,
    3. Zanette F,
    4. et al

    . Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int J Dev Neurosci 2007;25:47–51

    CrossRefPubMed
63. 63.↵
    1. De Stefano N,
    2. Filippi M

    . MR spectroscopy in multiple sclerosis. J Neuroimaging 2007;17(suppl 1):31S–35S

    CrossRefPubMedWeb of Science
64. 64.↵
    1. Gujar SK,
    2. Maheshwari S,
    3. Bjorkman-Burtscher I,
    4. et al

    . Magnetic resonance spectroscopy. J Neuroophthalmol 2005;25:217–26

    CrossRefPubMed